资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#PEG#
56篇内容 | 2159人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=e59c1400060, topicName=PEG, introduction=PEG, content=null, image=null, comments=56, allHits=2159, url=https://h5.medsci.cn/topic?id=14000, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=6469, tagList=[TagDto(tagId=6469, tagName=PEG)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1533524, encodeId=17b415335244e, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Front Immunol:PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关, objectType=article, longId=736354, objectId=8d4ce36354d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d4ce36354d3, replyNumber=0, likeNumber=162, createdTime=2022-08-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d4ce36354d3, moduleTitle=Front Immunol:PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d4ce36354d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533523, encodeId=89731533523f2, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Eur Urol:Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何?, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=87, createdTime=2022-06-27, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol:Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533522, encodeId=26871533522ea, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=JAMA Oncol:Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, objectType=article, longId=727101, objectId=5187e27101bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5187e27101bb, replyNumber=0, likeNumber=76, createdTime=2022-05-18, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5187e27101bb, moduleTitle=JAMA Oncol:Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5187e27101bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533521, encodeId=2474153352122, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Immunother Cancer:Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, objectType=article, longId=725499, objectId=bec0e25499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec0e25499db, replyNumber=0, likeNumber=0, createdTime=2022-04-28, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec0e25499db, moduleTitle=J Immunother Cancer:Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec0e25499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533520, encodeId=a4a7153352010, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), objectType=article, longId=220622, objectId=7e4422062262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4422062262, replyNumber=0, likeNumber=97, createdTime=2021-11-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4422062262, moduleTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4422062262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533519, encodeId=406015335192a, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH),已获得欧盟CHMP积极意见, objectType=article, longId=218729, objectId=4cd6218e291b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cd6218e291b, replyNumber=0, likeNumber=94, createdTime=2021-10-18, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cd6218e291b, moduleTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH),已获得欧盟CHMP积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cd6218e291b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533518, encodeId=be871533518e6, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM:Efpeglenatide治疗2型糖尿病的心血管和肾脏结局, objectType=article, longId=216606, objectId=acd4216606b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acd4216606b6, replyNumber=0, likeNumber=79, createdTime=2021-09-03, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acd4216606b6, moduleTitle=NEJM:Efpeglenatide治疗2型糖尿病的心血管和肾脏结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acd4216606b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533517, encodeId=0748153351ec9, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Urol Int:miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移, objectType=article, longId=214394, objectId=d7d421439443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7d421439443, replyNumber=0, likeNumber=97, createdTime=2021-07-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7d421439443, moduleTitle=Urol Int:miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7d421439443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533516, encodeId=5c061533516aa, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Clin Oncol:Bempegaldesleukin 联合 纳武利尤单抗(Nivolumab)一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=59, createdTime=2021-07-17, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol:Bempegaldesleukin 联合 纳武利尤单抗(Nivolumab)一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533515, encodeId=c199153351500, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Clin Oncol:Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, objectType=article, longId=214106, objectId=eb67214106de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb67214106de, replyNumber=0, likeNumber=84, createdTime=2021-07-14, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb67214106de, moduleTitle=J Clin Oncol:Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb67214106de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533514, encodeId=61261533514d0, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM:长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=101, createdTime=2021-07-02, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM:长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533513, encodeId=c8041533513b0, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM:Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, objectType=article, longId=208673, objectId=25e82086e3fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25e82086e3fe, replyNumber=0, likeNumber=91, createdTime=2021-03-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25e82086e3fe, moduleTitle=NEJM:Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25e82086e3fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533512, encodeId=bd93153351262, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Br J Cancer:ADI-PEG20联合顺铂治疗转移性恶性实体瘤, objectType=article, longId=207933, objectId=550020e93315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=550020e93315, replyNumber=0, likeNumber=82, createdTime=2021-03-07, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=550020e93315, moduleTitle=Br J Cancer:ADI-PEG20联合顺铂治疗转移性恶性实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=550020e93315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533511, encodeId=101915335118f, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=JCO:Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=79, createdTime=2021-02-11, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO:Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533510, encodeId=62421533510ee, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, objectType=article, longId=204053, objectId=0bbe204053d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbe204053d5, replyNumber=0, likeNumber=95, createdTime=2020-12-04, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbe204053d5, moduleTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbe204053d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533509, encodeId=412315335090c, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Blood:重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, objectType=article, longId=203528, objectId=9b0d20352851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0d20352851, replyNumber=0, likeNumber=71, createdTime=2020-11-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0d20352851, moduleTitle=Blood:重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0d20352851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533508, encodeId=19181533508e5, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性, objectType=article, longId=203223, objectId=8c5920322388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c5920322388, replyNumber=0, likeNumber=85, createdTime=2020-11-11, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c5920322388, moduleTitle=DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c5920322388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533507, encodeId=301e153350e57, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Pharmaceutics:壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, objectType=article, longId=202457, objectId=68f020245ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f020245ef3, replyNumber=0, likeNumber=86, createdTime=2020-10-26, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f020245ef3, moduleTitle=Pharmaceutics:壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68f020245ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533506, encodeId=bda21533506ef, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=EHA 2020:III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=65, createdTime=2020-06-15, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020:III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533505, encodeId=4ac11533505ac, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Lancet haematol:Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效!, objectType=article, longId=187425, objectId=b82918e4252e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82918e4252e, replyNumber=0, likeNumber=60, createdTime=2020-02-06, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82918e4252e, moduleTitle=Lancet haematol:Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b82918e4252e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
PEG
2020-05-29
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Front Immunol:PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关
162
0
2022-08-21
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Eur Urol:Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何?
87
0
2022-06-27
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
JAMA Oncol:Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后
76
0
2022-05-18
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
J Immunother Cancer:Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌
0
0
2022-04-28
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
美国FDA核准BESREMi® (Ropeginterferon α-2b)
97
0
2021-11-21
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH),已获得欧盟CHMP积极意见
94
0
2021-10-18
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
NEJM:Efpeglenatide治疗2型糖尿病的心血管和肾脏结局
79
0
2021-09-03
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Urol Int:miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移
97
0
2021-07-20
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
J Clin Oncol:Bempegaldesleukin 联合 纳武利尤单抗(Nivolumab)一线治疗转移性黑色素瘤
59
0
2021-07-17
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
J Clin Oncol:Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性
84
0
2021-07-14
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
NEJM:长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用
101
0
2021-07-02
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
NEJM:Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab
91
0
2021-03-20
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Br J Cancer:ADI-PEG20联合顺铂治疗转移性恶性实体瘤
82
0
2021-03-07
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
JCO:Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效
79
0
2021-02-11
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期
95
0
2020-12-04
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Blood:重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病
71
0
2020-11-20
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性
85
0
2020-11-11
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Pharmaceutics:壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎
86
0
2020-10-26
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
EHA 2020:III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著
65
0
2020-06-15
回复
wleon8899
(审核中...)
关注
已关注
前往app查看评论内容
#PEG#
Lancet haematol:Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效!
60
0
2020-02-06
回复
共56条
首页
上一页
下一页
尾页
页码:
1
/3页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务